Who is sponsoring NCT05921565?

NCT05921565 is sponsored by Northwestern University.

What drugs are being tested in NCT05921565?

Interventions in NCT05921565: Interventional Behavioral Arm.

What condition does NCT05921565 study?

NCT05921565 studies Weight Reduction, Adherence, Patient.

Is NCT05921565 still recruiting?

NCT05921565 is currently completed. Last updated 9 November 2023.

Last reviewed 2023-11-09 · How we verify

NCT05921565: M-POWER

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

M-POWER Feasibility Study

Completed NA Last updated 9 November 2023

What this trial tests

NA trial testing Interventional Behavioral Arm in Weight Reduction in 26 participants. Completed in 8 November 2023.

Timeline

11 March 2019

Primary endpoint
8 November 2023

8 November 2023

Quick facts

Lead sponsor	Northwestern University
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	26
Start date	11 March 2019
Primary completion	8 November 2023
Estimated completion	8 November 2023
Sites	1 location across United States

Drugs / interventions tested

Interventional Behavioral Arm

Conditions studied

Weight Reduction — all drugs for Weight Reduction →
Adherence, Patient — all drugs for Adherence, Patient →

Sponsor

Northwestern University

Who can join

Adults 18 to 84, any sex, with Weight Reduction or Adherence, Patient. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to test a new weight loss intervention designed for cancer survivors who have heart disease or cardiometabolic conditions. The investigators want to determine whether this study is feasible and acceptable to participants. The investigators also want to learn more about how cancer survivors take their medications.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Weight Reduction

Currently open trials in the same condition.

NCT07513168 — Low-Dose Semaglutide for Weight Loss in Obese Non-Diabetic Pakistani Adults · Phase 4 · recruiting

Other Northwestern University trials

Trials by the same sponsor.

NCT06545695 — Epidermal Growth Factor Receptor Inhibition for Keratinopathies · Phase 1, PHASE2 · not yet recruiting
NCT07261657 — N-803 in Patients With Progressive Synovial Sarcoma and Myxoid/Round Cell Liposarcoma Previously Treated With Adoptive C · EARLY_PHASE1 · not yet recruiting
NCT07392775 — ALDH2 Genetic Testing in East Asian Community · NA · not yet recruiting
NCT06886776 — Implementing A Secure Firearm Storage Program in Illinois Health Centers in Partnership With AllianceChicago and the Ill · NA · not yet recruiting
NCT07469176 — Co-Designing and Evaluating Additional Mothers and Babies Program Content for Expectant and New Parents of Children With · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05921565 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Northwestern University
Last refreshed: 9 November 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05921565.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing